Immix Biopharma (IMMX) Operating Leases (2024 - 2026)

Immix Biopharma has disclosed Operating Leases across 3 years of filings, most recently posting $912343.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $912343.0, down 7.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $912343.0 (down 7.95% YoY), and the FY2025 annual result was $933625.0, down 7.52% from the prior year.
• Operating Leases came in at $912343.0 for Q1 2026 at Immix Biopharma, down from $933625.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.1 million in Q1 2024 to a low of $912343.0 in Q1 2026.
• The 3-year median for Operating Leases is $991126.0 (2025), against an average of $990235.6.
• Across the five-year window, Operating Leases decreased 5.97% in 2025 and retreated 7.95% in 2026, its largest moves.
• Immix Biopharma's Operating Leases stood at $1.0 million in 2024, then decreased by 7.52% to $933625.0 in 2025, then retreated by 2.28% to $912343.0 in 2026.
• The last three Operating Leases figures came in at $912343.0 (Q1 2026), $933625.0 (Q4 2025), and $965053.0 (Q3 2025), per Business Quant data.